N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline form and processes

摘要

The present invention provides a novel antagonist: N-((1R,2S,5R)-5-(<Italic>tert-</Italic>butylamino)-2-((S)-3-(7-<Italic>tert</Italic>-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclo hexyl)acetamide:
<Chemistry id="chema01" num="0001"><Image id="ia01" he="70" wi="58" file="IMGA0001.TIF" imgContent="chem" imgFormat="TIFF" /></Chemistry>
or a pharmaceutically acceptable salt, solvate or prodrug, thereof, having unexpected dual CCR-2 and CCR-5 receptor activity. Crystalline forms, metabolites, pharmaceutical compositions containing the same and methods of using the same as agents for the treatment of kidney diseases are also disclosed. The present disclosure also provides processes for preparing compounds of Formula (I) as provided herein, including N-((1R,2S,5R)-5-(<Italic>tert</Italic>-butylamino)-2-((S)-3-(7-<Italic>tert</Italic>-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide. Compounds that are useful intermediates of the process are also provided herein.